Please assess the completion status of the following clinical trial:

Trial Title: Study of Extensive Clinical Target Volumes in Postoperative Radiotherapy Concurrent With Chemotherapy for Esophageal Squamous Cell Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Joined the study voluntarily and signed informed consent form;~* Age 18-75;~* ECOG 0-2;~* Esophageal squamous cell carcinoma, radical surgery ≤ 3 months, R0 resection;~* The operative incision healed well;~* T3-4N0M0, T1-4N1-3M0 (according to AJCC2009);~* No radiotherapy, chemotherapy or other treatments pre (post) surgery;~* PS ECOG 0-2;~* Life expectancy of more than 3 months;~* Hemoglobin (Hb) ≥ 9 g/dL • WBC ≥ 3 x 109/L, Neutrophils (ANC ) ≥ 1.5 x 109/L • platelet count (Pt) ≥ 100 x 109/L • Hepatic function: ALAT and ASAT \< 2.5 x ULN, TBIL\< 1.5 x ULN • Renal function: creatinine \< 1.5 x ULN~* No immuno-deficiency;~* Use of an effective contraceptive for adults to prevent pregnancy.~Exclusion Criteria:~* Complete esophageal obstruction after surgery, Esophageal perforation, Haematemesis;~* Other malignant tumors, except for skin basal cell carcinoma, or cervical carcinoma in situ, who survived with no evidence disease for over 3 years;~* Participation in other interventional clinical trials within 30 days;~* Pregnant or breast-feeding women or people during the birth-period who refused to take contraceptives;~* Drug addiction, Alcoholism or AIDS;~* Uncontrolled seizures or psychiatric diseases, loss of control over their own behavior;~* Unsuitable to be enrolled in the trial in the opinion of the investigators.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Chemo-radiation group (Type: EXPERIMENTAL): A total dose of 45Gy will be delivered in 25 fractions at 1.8Gy/fraction, 5 fractions per week in 5 weeks.~The CTV encompassed the bilateral supraclavicular region, all mediastinal lymph nodes, the anastomosis site, and the left gastric and celiac nodes.~Paclitaxel 50mg/m2/d, ivgtt over 3 hours, d1; Carboplatin AUC=2, ivgtt, d1; qw\*5

Based on this trial design, predict the completion outcome and termination type (if applicable).